Department of Urology, Northwick Park Hospital, London, UK.
BJU Int. 2010 Oct;106(7):1017-20. doi: 10.1111/j.1464-410X.2010.09294.x. Epub 2010 Mar 16.
To determine the prevalence of antimicrobial resistance in intestinal flora of patients undergoing transrectal ultrasonography (TRUS)-guided prostate biopsies (TGB) and to examine if this information is useful in selecting appropriate antimicrobial agents for prophylaxis and treatment of biopsy-associated infections.
In 2007 and 2008, rectal swabs were cultured from patients before undergoing TGB. Antimicrobial sensitivity of coliforms to amikacin, ciprofloxacin and coamoxiclav was determined. Laboratory records were used to identify patients who had bacteraemia or significant bacteriuria within 30 days of the TGB and the antimicrobial sensitivity pattern of these organisms were compared to those from the rectal swab.
Of 592 patients who had TGB, 445 (75.1%) had a rectal swab beforehand; 0.2%,10.6% and 13.3% of the coliforms were resistant to amikacin, ciprofloxacin and coamoxiclav, respectively. After TGB, six patients presented with urinary tract infections (UTI) and two with bacteraemia. All the infections were caused by coliforms except one UTI which was caused by ciprofloxacin-sensitive Pseudomonas aeruginosa. The blood culture isolates were sensitive to amikacin but resistant to ciprofloxacin and coamoxiclav. All the coliforms in the urine were resistant to ciprofloxacin but sensitive to coamoxiclav. Urine isolates were not tested for amikacin sensitivity. There was a strong correlation between the antimicrobial sensitivity of the coliforms from the rectal swabs and those cultured from urine or blood in both patients for amikacin, six of eight for ciprofloxacin and seven of eight for coamoxiclav.
Our study shows that in the coliforms in the bowel flora of our local population there is a relatively high level of resistance to ciprofloxacin and coamoxiclav, and very low level of resistance to amikacin. As there was a strong correlation between the antimicrobial sensitivity of organisms causing infections after TGB and those isolated from the rectal swabs, we conclude that rectal swab cultures before TGB provide useful evidence for selecting appropriate antimicrobials for prophylaxis and treatment of TGB-associated infections.
确定接受经直肠超声引导前列腺活检(TGB)的患者肠道菌群中抗菌药物耐药的流行情况,并探讨这些信息是否有助于选择合适的抗菌药物预防和治疗活检相关性感染。
在 2007 年和 2008 年,对接受 TGB 的患者进行直肠拭子培养。检测大肠埃希菌对抗阿米卡星、环丙沙星和复方新诺明的药敏情况。利用实验室记录,确定在 TGB 后 30 天内发生菌血症或显著菌尿的患者,并比较这些患者的微生物药敏模式与直肠拭子培养的结果。
在 592 例行 TGB 的患者中,有 445 例(75.1%)在接受 TGB 前进行了直肠拭子培养;大肠埃希菌对阿米卡星、环丙沙星和复方新诺明的耐药率分别为 0.2%、10.6%和 13.3%。TGB 后,6 例患者出现尿路感染(UTI),2 例患者出现菌血症。所有感染均由大肠埃希菌引起,除 1 例由对环丙沙星敏感的铜绿假单胞菌引起的 UTI 外。血培养分离株对阿米卡星敏感,但对环丙沙星和复方新诺明耐药。所有尿培养分离株对环丙沙星耐药,但对复方新诺明敏感。未对尿分离株进行阿米卡星药敏检测。在阿米卡星、环丙沙星和复方新诺明的药敏检测中,患者直肠拭子和尿液或血液中大肠埃希菌的药敏结果具有很强的相关性,6/8 例对阿米卡星、8/8 例对环丙沙星、8/8 例对复方新诺明。
本研究表明,在本地区人群肠道菌群的大肠埃希菌中,对环丙沙星和复方新诺明的耐药率相对较高,对阿米卡星的耐药率很低。由于 TGB 后引起感染的微生物与直肠拭子培养分离的微生物之间具有很强的相关性,我们认为 TGB 前进行直肠拭子培养可为预防和治疗 TGB 相关性感染选择合适的抗菌药物提供有用的依据。